Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 13, 152

Restricted Mean Survival Time: An Alternative to the Hazard Ratio for the Design and Analysis of Randomized Trials With a Time-To-Event Outcome


Restricted Mean Survival Time: An Alternative to the Hazard Ratio for the Design and Analysis of Randomized Trials With a Time-To-Event Outcome

Patrick Royston et al. BMC Med Res Methodol.


Background: Designs and analyses of clinical trials with a time-to-event outcome almost invariably rely on the hazard ratio to estimate the treatment effect and implicitly, therefore, on the proportional hazards assumption. However, the results of some recent trials indicate that there is no guarantee that the assumption will hold. Here, we describe the use of the restricted mean survival time as a possible alternative tool in the design and analysis of these trials.

Methods: The restricted mean is a measure of average survival from time 0 to a specified time point, and may be estimated as the area under the survival curve up to that point. We consider the design of such trials according to a wide range of possible survival distributions in the control and research arm(s). The distributions are conveniently defined as piecewise exponential distributions and can be specified through piecewise constant hazards and time-fixed or time-dependent hazard ratios. Such designs can embody proportional or non-proportional hazards of the treatment effect.

Results: We demonstrate the use of restricted mean survival time and a test of the difference in restricted means as an alternative measure of treatment effect. We support the approach through the results of simulation studies and in real examples from several cancer trials. We illustrate the required sample size under proportional and non-proportional hazards, also the significance level and power of the proposed test. Values are compared with those from the standard approach which utilizes the logrank test.

Conclusions: We conclude that the hazard ratio cannot be recommended as a general measure of the treatment effect in a randomized controlled trial, nor is it always appropriate when designing a trial. Restricted mean survival time may provide a practical way forward and deserves greater attention.


Figure 1
Figure 1
Example of sample sizes as a function of the time horizon t for PH (solid lines) and non-PH (dashed lines) trial designs. The designs assume recruitment over K1 = 5 yr and follow-up over K2 = 3 yr.
Figure 2
Figure 2
Percent maturity (pmat) and power curves as a function of t for the RE04 trial. Vertical lines show tfinal.
Figure 3
Figure 3
Evolution over time ( t ) of z -statistics for RMST (truncated, solid lines; non-truncated, short dashed lines) and Cox (truncated, long dashed lines) tests in four randomized controlled trials in cancer.

Similar articles

See all similar articles

Cited by 85 PubMed Central articles

See all "Cited by" articles


    1. Royston P, Parmar MKB. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med. 2011;13:2409–2421. doi: 10.1002/sim.4274. - DOI - PubMed
    1. Schemper M, Wakounig S, Heinze G. The estimation of average hazard ratios by weighted Cox regression. Stat Med. 2009;13:2473–2489. doi: 10.1002/sim.3623. - DOI - PubMed
    1. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin - paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;13:947–957. doi: 10.1056/NEJMoa0810699. - DOI - PubMed
    1. Kristensen G, Perren T, Qian W, Pfisterer J, Ledermann JA, Joly F, Carey MS. Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. J Clin Oncol. 2011;13(S):LBA5006.
    1. Andersen PK, Perme MP. Pseudo-observations in survival analysis. Stat Methods Med Res. 2010;13:71–99. doi: 10.1177/0962280209105020. - DOI - PubMed

MeSH terms